Table 2.
Finished Phase II studies
| Target | Agents | Name of Trial and Setting | Phase | Number of patients | PFS (mo) | OS (mo) | Results |
| HER-2 | Lapatinib | S0413, First line | II | 47 | 1.9 | 4.8 | Positive |
| HER-2 | Lapatinib plus ECF or ECX vs placebo plus ECF or ECX | EORTC 40071, First line | II | 28 | 7.1 vs 5.9 | 13.8 vs 10.1 | Negative1 |
| HER-2 | MK-2206 (AKT inhibitor) | S1005, Second line | II | 70 | 1.8 | 5.1 | Negative |
| Pan-HER | Saracatinib (Src inhibitor) | NN, ≥ Second line | II | 21 | 1.8 | 7.8 | Negative |
| Pan-HER | Dacomitinib | NN, ≥ Second line | II | 27 | 2.1 | 7.1 | Positive |
| EGFR | Cetuximab plus mFOLFOX6 | NN, First line | II | 40 | 5.5 | 9.9 | Positive |
| EGFR | Cetuximab plus FOLFIRI | NN, First line | II | 49 | 9.0 | 16.5 | Positive |
| EGFR | Panitumumab with dose dense DCF | NN, First line | II | 52 | 4.8 | 9.4 | Positive |
| VEGF | Bevacizumab plus irinotecan and cisplatin | NN, First line | II | 47 | 8.3 | 12.3 | Positive |
| VEGF | Bevacizumab plus docetaxel/oxaliplatin | NN, First line | II | 38 | 6.6 | 11.1 | Positive |
| m-TOR | Everolimus 10 mg | NN, ≥ Second line | II | 53 | 2.7 | 10.1 | Positive |
1
Early terminated. VEGF: Vascular endothelial growth factor; m-TOR: Mammalian target of rapamycin; NN: No specific study name was defined.